Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders)
  4. Volume 25, Issue 3
  5. Article
Volume 25, Issue 3
  • ISSN: 1871-5303
  • E-ISSN: 2212-3873

Abstract

In recent years, the prevalence of diabetes has gradually increased and has become one of the main chronic non-communicable diseases, threatening the lives of people. Diabetic complications are characterized by high incidence and poor prognosis. Once they occur, conventional drugs are difficult to reverse, so it is extremely urgent to seek new drugs to treat diabetes and complications. Puerarin is an isoflavone derivative isolated from the root of Pueraria lobata; it has the functions of regulating blood glucose and lipids, protecting pancreatic β cells, improving insulin resistance, anti-inflammation, anti-oxidation, and may become a potential supplement and substitute drug for diabetes and complications. Although puerarin is effective in the treatment of diabetes and complications, there is a lack of induction and collation of related mechanisms. This paper reviewed the research progress of the protective effect of puerarin on diabetes mellitus and its complications in recent years and discussed its related mechanism, providing a theoretical basis for the application of puerarin in the treatment of diabetes.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/emiddt/10.2174/0118715303287050240223073217
2024-03-06
2025-01-18

  • From This Site

    /content/journals/emiddt/10.2174/0118715303287050240223073217
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. DeFronzoR.A. FerranniniE. GroopL. HenryR.R. HermanW.H. HolstJ.J. HuF.B. KahnC.R. RazI. ShulmanG.I. SimonsonD.C. TestaM.A. WeissR. Type 2 diabetes mellitus.Nat. Rev. Dis. Primers2015111501910.1038/nrdp.2015.19 27189025
     [Google Scholar]
  2. SacksD.B. ArnoldM. BakrisG.L. BrunsD.E. HorvathA.R. LernmarkÅ. MetzgerB.E. NathanD.M. KirkmanM.S. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus.Diabetes Care20234610e151e19910.2337/dci23‑0036 37471273
     [Google Scholar]
  3. Ismail-BeigiF. Clinical practice. Glycemic management of type 2 diabetes mellitus.N. Engl. J. Med.2012366141319132710.1056/NEJMcp1013127 22475595
     [Google Scholar]
  4. LiY. YaoZ. YueW. ZhangC. GaoS. WangC. Reusable, non-invasive, and ultrafast radio frequency biosensor based on optimized integrated passive device fabrication process for quantitative detection of glucose levels.Sensors2020206156510.3390/s20061565 32168963
     [Google Scholar]
  5. LeslieR.D. MaR.C.W. FranksP.W. NadeauK.J. PearsonE.R. RedondoM.J. Understanding diabetes heterogeneity: Key steps towards precision medicine in diabetes.Lancet Diabetes Endocrinol.2023111184886010.1016/S2213‑8587(23)00159‑6 37804855
     [Google Scholar]
  6. WeiY. HerzogK. AhlqvistE. AnderssonT. NyströmT. ZhanY. TuomiT. CarlssonS. All-cause mortality and cardiovascular and microvascular diseases in latent autoimmune diabetes in adults.Diabetes Care202346101857186510.2337/dc23‑0739 37635682
     [Google Scholar]
  7. ZhouJ. ChenB. Retinal cell damage in diabetic retinopathy.Cells2023129134210.3390/cells12091342 37174742
     [Google Scholar]
  8. WangT. WangY.Y. ShiM.Y. LiuL. Mechanisms of action of natural products on type 2 diabetes.World J. Diabetes202314111603162010.4239/wjd.v14.i11.1603 38077803
     [Google Scholar]
  9. ZhouY.X. ZhangH. PengC. Puerarin: A review of pharmacological effects.Phytother. Res.201428796197510.1002/ptr.5083 24339367
     [Google Scholar]
  10. ZhengQ.H. LiX.L. MeiZ.G. XiongL. MeiQ.X. WangJ.F. TanL.J. YangS.B. FengZ.T. Efficacy and safety of puerarin injection in curing acute ischemic stroke.Medicine2017961e580310.1097/MD.0000000000005803 28072733
     [Google Scholar]
  11. GaoZ. WeiB. QianC. Puerarin injection for treatment of unstable angina pectoris: A meta-analysis and systematic review.Int. J. Clin. Exp. Med.2015891457714594 26628941
     [Google Scholar]
  12. YuanM. LiuG. ZhengX. LiP. LiuJ. WangS. CaoY. Effects of puerarin combined with conventional therapy on ischemic stroke.Exp. Ther. Med.20171442943294610.3892/etm.2017.4922 29042907
     [Google Scholar]
  13. WuJ. ZhangX. ZhangB. Efficacy and safety of puerarin injection in treatment of diabetic peripheral neuropathy: A systematic review and meta-analysis of randomized controlled trials. J. trad.Chin. Med.2014344401410
     [Google Scholar]
  14. XieB. WangQ. ZhouC. WuJ. XuD. Efficacy and safety of the injection of the traditional chinese medicine puerarin for the treatment of diabetic peripheral neuropathy: A systematic review and meta-analysis of 53 randomized controlled trials.Evidencebased Complem. Altern. Med.20182834650
     [Google Scholar]
  15. ChenX. YuJ. ShiJ. Management of diabetes mellitus with puerarin, a natural isoflavone from Pueraria lobata.Am. J. Chin. Med.20184681771178910.1142/S0192415X18500891 30525896
     [Google Scholar]
  16. LiS. LiY. WuD. XuY. YanH. HuJ.N. Metal-polyphenol microgels for oral delivery of puerarin to alleviate the onset of diabetes.Drug Deliv. Transl. Res.202414375777210.1007/s13346‑023‑01428‑2 37768531
     [Google Scholar]
  17. ChenQ. WangL. WeiX. ChenM. ZhangX. MoR. HuangR. LiangT. XuX. Puerarin alleviates diabetic nephropathy by inhibiting Caspase-1-mediated pyroptosis.J. Pharm. Pharmacol.20241211310.1093/jpp/rgad113 38215026
     [Google Scholar]
  18. LiX. WangJ. YanJ. HeJ.C. LiY. ZhongY. Additive renal protective effects between arctigenin and puerarin in diabetic kidney disease.Biomed. Pharmacother.202417111610710.1016/j.biopha.2023.116107 38215692
     [Google Scholar]
  19. HouB. MaP. YangX. ZhaoX. ZhangL. ZhaoY. HeP. ZhangL. DuG. QiangG. In silico prediction and experimental validation to reveal the protective mechanism of Puerarin against excessive extracellular matrix accumulation through inhibiting ferroptosis in diabetic nephropathy.J. Ethnopharmacol.2024319Pt 211728110.1016/j.jep.2023.117281 37797872
     [Google Scholar]
  20. LiuY. HuZ. WangJ. LiaoY. ShuL. Puerarin alleviates depressive-like behaviors in high-fat diet-induced diabetic mice via modulating hippocampal GLP-1R/BDNF/TrkB signaling.Nutr. Neurosci.20232610997101010.1080/1028415X.2022.2112439 36039913
     [Google Scholar]
  21. ChenX. WangL. WuY. SongS. MinH. YangY. HeX. LiangQ. YiL. WangY. GaoQ. Effect of puerarin in promoting fatty acid oxidation by increasing mitochondrial oxidative capacity and biogenesis in skeletal muscle in diabetic rats.Nutr. Diabetes201881110.1038/s41387‑017‑0009‑6 29330446
     [Google Scholar]
  22. YangF. DongX. GuoY. Effects of puerarin on rats with type 2 diabetes mellitus.J. Appl. Phys.2019354355358
     [Google Scholar]
  23. ZhuC. CaiT. JinY. ChenJ. LiuG. XuN. ShenR. ChenY. HanL. WangS. WuC. ZhuM. Artificial intelligence and network pharmacology based investigation of pharmacological mechanism and substance basis of Xiaokewan in treating diabetes.Pharmacol. Res.202015910493510.1016/j.phrs.2020.104935 32464328
     [Google Scholar]
  24. LiuY. QiuY. ChenQ. HanX. CaiM. HaoL. Puerarin suppresses the hepatic gluconeogenesis via activation of PI3K/Akt signaling pathway in diabetic rats and HepG cells.Biomedecine & pharma.2021137111325
     [Google Scholar]
  25. ChenX. YiL. SongS. WangL. LiangQ. WangY. WuY. GaoQ. Puerarin attenuates palmitate-induced mitochondrial dysfunction, impaired mitophagy and inflammation in L6 myotubes.Life Sci.2018206849210.1016/j.lfs.2018.05.041 29802940
     [Google Scholar]
  26. NairG.G. TzanakakisE.S. HebrokM. Emerging routes to the generation of functional β-cells for diabetes mellitus cell therapy.Nat. Rev. Endocrinol.202016950651810.1038/s41574‑020‑0375‑3 32587391
     [Google Scholar]
  27. YongJ. JohnsonJ.D. ArvanP. HanJ. KaufmanR.J. Therapeutic opportunities for pancreatic β-cell ER stress in diabetes mellitus.Nat. Rev. Endocrinol.202117845546710.1038/s41574‑021‑00510‑4 34163039
     [Google Scholar]
  28. LiangT. XuX. YeD. ChenW. GaoB. HuangY. Caspase/AIF/apoptosis pathway: A new target of puerarin for diabetes mellitus therapy.Mol. Biol. Rep.20194654787479710.1007/s11033‑019‑04925‑1 31228042
     [Google Scholar]
  29. WangC. YaoJ. JuL. WenX. ShuL. Puerarin ameliorates hyperglycemia in HFD diabetic mice by promoting β-cell neogenesis via GLP-1R signaling activation.Phytomedicine20207015322210.1016/j.phymed.2020.153222 32361558
     [Google Scholar]
  30. JamesD.E. StöckliJ. BirnbaumM.J. The aetiology and molecular landscape of insulin resistance.Nat. Rev. Mol. Cell Biol.2021221175177110.1038/s41580‑021‑00390‑6 34285405
     [Google Scholar]
  31. YuQ. HanW. ZhuY. ZhaiH. Effect of puerarin on type II diabetes mellitus with orthopaedic footwear.Pak. J. Pharm. Sci.2017305(Special)18991903 29084664
     [Google Scholar]
  32. ChenX. WangL. FanS. SongS. MinH. WuY. HeX. LiangQ. WangY. YiL. GaoQ. Puerarin acts on the skeletal muscle to improve insulin sensitivity in diabetic rats involving μ-opioid receptor.Eur. J. Pharmacol.201881811512310.1016/j.ejphar.2017.10.033 29061371
     [Google Scholar]
  33. GaoJ. LiuM. GuoZ. HuC. FengZ. YanJ. Puerarin alleviates insulin resistance in type 2 diabetic mice by modulating fetuin B-AMPK/ACC signaling pathway in the liver.J. South. Med. Uni.2021416839846
     [Google Scholar]
  34. HeydarpourF. SajadimajdS. MirzaraziE. HaratipourP. JoshiT. FarzaeiM.H. KhanH. EcheverríaJ. Involvement of TGF-β and autophagy pathways in pathogenesis of diabetes: a comprehensive review on biological and pharmacological insights.Front. Pharmacol.20201149875810.3389/fphar.2020.498758 33041786
     [Google Scholar]
  35. NiemannB. RohrbachS. MillerM.R. NewbyD.E. FusterV. KovacicJ.C. Oxidative stress and cardiovascular risk: Obesity, diabetes, smoking, and pollution.J. Am. Coll. Cardiol.201770223025110.1016/j.jacc.2017.05.043 28683970
     [Google Scholar]
  36. LiZ. WangS. WangX. GaoP. ZhangS. MoY. ZhaoD. DaiL. Pharmacodynamic interactions between puerarin and metformin in type-2 diabetic rats.Molecules20222721719710.3390/molecules27217197 36364022
     [Google Scholar]
  37. WangT. LiuY. HuangC. MansaiH. WeiW. ZhangX. LiX. LiuS. YangS. Puerarin promotes MIN6 cell survival by reducing cellular reactive oxygen species.Mol. Med. Rep.20181757281728610.3892/mmr.2018.8731 29568901
     [Google Scholar]
  38. HouB.Y. ZhaoY.R. MaP. XuC.Y. HeP. YangX.Y. ZhangL. QiangG.F. DuG.H. Hypoglycemic activity of puerarin through modulation of oxidative stress and mitochondrial function via AMPK.Chin. J. Nat. Med.2020181181882610.1016/S1875‑5364(20)60022‑X 33308602
     [Google Scholar]
  39. XueB. WangL. ZhangZ. WangR. XiaX. HanP. CaoL. LiuY. SunL. Puerarin may protect against Schwann cell damage induced by glucose fluctuation.J. Nat. Med.201771347248110.1007/s11418‑016‑1067‑0 28181078
     [Google Scholar]
  40. ChenX. QianL. WangB. ZhangZ. LiuH. ZhangY. LiuJ. Synergistic hypoglycemic effects of pumpkin polysaccharides and puerarin on type ii diabetes mellitus mice.Molecules201924595510.3390/molecules24050955 30857163
     [Google Scholar]
  41. DengW. WangH. WuB. ZhangX. Selenium-layered nanoparticles serving for oral delivery of phytomedicines with hypoglycemic activity to synergistically potentiate the antidiabetic effect.Acta Pharm. Sin. B201991748610.1016/j.apsb.2018.09.009 30766779
     [Google Scholar]
  42. KuryłowiczA. KoźniewskiK. Anti-inflammatory strategies targeting metaflammation in type 2 diabetes.Molecules2020259222410.3390/molecules25092224 32397353
     [Google Scholar]
  43. KongM. XieK. LvM. LiJ. YaoJ. YanK. WuX. XuY. YeD. Anti-inflammatory phytochemicals for the treatment of diabetes and its complications: Lessons learned and future promise.Biomed. & pharma.2021133110975
     [Google Scholar]
  44. TuY. GongC. DingL. LiuX. LiT. HuF. WangS. XiongC. LiangS. XuH. A high concentration of fatty acids induces TNF-α as well as NO release mediated by the P2X4 receptor, and the protective effects of puerarin in RAW264.7 cells.Food Funct.20178124336434610.1039/C7FO00544J 28937704
     [Google Scholar]
  45. XuW. TangM. WangJ. WangL. Anti-inflammatory activities of puerarin in high-fat diet-fed rats with streptozotocin-induced gestational diabetes mellitus.Mol. Biol. Rep.202047107537754610.1007/s11033‑020‑05816‑6 32946041
     [Google Scholar]
  46. WuT. LiuC. HuangY. LiS. WangY. Simultaneous screening and isolation of activated constituents from Puerariae Flos by ultrafiltration with liquid chromatography and mass spectrometry combined with high‐speed counter‐current chromatography.J. Sep. Sci.201841244458446810.1002/jssc.201800691 30444083
     [Google Scholar]
  47. DongS. ZhangM. NiuH. JiangK. JiangJ. MaY. WangX. MengS. Upregulation of UDP-glucuronosyltransferases 1a1 and 1a7 Are involved in altered puerarin pharmacokinetics in type II diabetic rats.Molecules2018236148710.3390/molecules23061487 29925761
     [Google Scholar]
  48. ForbesJ.M. CooperM.E. Mechanisms of diabetic complications.Physiol. Rev.201393113718810.1152/physrev.00045.2011 23303908
     [Google Scholar]
  49. ChilelliN.C. BurlinaS. LapollaA. AGEs, rather than hyperglycemia, are responsible for microvascular complications in diabetes: A “glycoxidation-centric” point of view.Nutr. Metab. Cardiovasc. Dis.2013231091391910.1016/j.numecd.2013.04.004 23786818
     [Google Scholar]
  50. TanY. ZhangZ. ZhengC. WintergerstK.A. KellerB.B. CaiL. Mechanisms of diabetic cardiomyopathy and potential therapeutic strategies: preclinical and clinical evidence.Nat. Rev. Cardiol.202017958560710.1038/s41569‑020‑0339‑2 32080423
     [Google Scholar]
  51. EckelR.H. BornfeldtK.E. GoldbergI.J. Cardiovascular disease in diabetes, beyond glucose.Cell Metab.20213381519154510.1016/j.cmet.2021.07.001 34289375
     [Google Scholar]
  52. JiangZ. CuiX. QuP. ShangC. XiangM. WangJ. Roles and mechanisms of puerarin on cardiovascular disease: A review.Biomed. Pharmacother.202214711265510.1016/j.biopha.2022.112655 35066299
     [Google Scholar]
  53. YinM.S. ZhangY.C. XuS.H. LiuJ.J. SunX.H. LiangC. WangY. LiJ. WangF.W. WangQ.L. MuY.L. Puerarin prevents diabetic cardiomyopathy in vivo and in vitro by inhibition of inflammation.J. Asian Nat. Prod. Res.201921547649310.1080/10286020.2017.1405941 29322879
     [Google Scholar]
  54. GuoB.Q. XuJ.B. XiaoM. DingM. DuanL.J. Puerarin reduces ischemia/reperfusion-induced myocardial injury in diabetic rats via upregulation of vascular endothelial growth factor A/angiotensin-1 and suppression of apoptosis.Mol. Med. Rep.20181757421742710.3892/mmr.2018.8754 29568939
     [Google Scholar]
  55. JintaoX. NanqianZ. YupingY. YunJ. YueQ. YanhuaL. JunxiuL. XinqiaoT. YalingY. PengL. Puerarin-loaded ultrasound microbubble contrast agent used as sonodynamic therapy for diabetic cardiomyopathy rats.Colloids Surf. B Biointerfaces202019011088710.1016/j.colsurfb.2020.110887 32113166
     [Google Scholar]
  56. LianD. YuanH. YinX. WuY. HeR. HuangY. ChenY. Puerarin inhibits hyperglycemia-induced inter-endothelial junction through suppressing endothelial Nlrp3 inflammasome activation via ROS-dependent oxidative pathway.Phytomedicine20195531031910.1016/j.phymed.2018.10.013 30385134
     [Google Scholar]
  57. OshimaM. ShimizuM. YamanouchiM. ToyamaT. HaraA. FuruichiK. WadaT. Trajectories of kidney function in diabetes: A clinicopathological update.Nat. Rev. Nephrol.2021171174075010.1038/s41581‑021‑00462‑y 34363037
     [Google Scholar]
  58. XuY. XiongY. XuC. XuC. Standard puerarin prevents diabetic renal damage by inhibiting mirna-140-5p expression.Diabetes Metab. Syndr. Obes.2020133947395810.2147/DMSO.S273952 33122931
     [Google Scholar]
  59. XuX. ChenB. HuangQ. WuY. LiangT. The effects of puerarin on autophagy through regulating of the PERK/eIF2α/] ATF4 signaling pathway influences renal function in diabetic nephropathy.Diabetes Metab. Syndr. Obes.2020132583259210.2147/DMSO.S256457 32765037
     [Google Scholar]
  60. ZhongY. LeeK. HeJ.C. SIRT1 Is a potential drug target for treatment of diabetic kidney disease.Front. Endocrinol.2018962410.3389/fendo.2018.00624 30386303
     [Google Scholar]
  61. LiX. ZhuQ. ZhengR. YanJ. WeiM. FanY. DengY. ZhongY. Puerarin attenuates diabetic nephropathy by promoting autophagy in podocytes.Front. Physiol.2020117310.3389/fphys.2020.00073 32116781
     [Google Scholar]
  62. LiX. CaiW. LeeK. LiuB. DengY. ChenY. ZhangX. HeJ.C. ZhongY. Puerarin attenuates diabetic kidney injury through the suppression of NOX4 expression in podocytes.Sci. Rep.2017711460310.1038/s41598‑017‑14906‑8 29097815
     [Google Scholar]
  63. ZhuQ. YangS. WeiC. LuG. LeeK. HeJ.C. LiuR. ZhongY. Puerarin attenuates diabetic kidney injury through interaction with Guanidine nucleotide‐binding protein Gi subunit alpha‐1 (Gnai1) subunit.J. Cell. Mol. Med.202226143816382710.1111/jcmm.17414 35678269
     [Google Scholar]
  64. ZhuQ. ZhouQ. LuoX. ZhangX. LiS. Combination of canagliflozin and puerarin alleviates the lipotoxicity to diabetic kidney in mice.Korean J. Physiol. Pharmacol.202327322123010.4196/kjpp.2023.27.3.221 37078296
     [Google Scholar]
  65. BarroL. HsiaoJ. ChenC. ChangY. HsiehM. Cytoprotective effect of liposomal puerarin on high glucose-induced injury in rat mesangial cells.Antioxidants20211081177
     [Google Scholar]
  66. AntonettiD.A. SilvaP.S. StittA.W. Current understanding of the molecular and cellular pathology of diabetic retinopathy.Nat. Rev. Endocrinol.202117419520610.1038/s41574‑020‑00451‑4 33469209
     [Google Scholar]
  67. ZhangD. LiM. Puerarin prevents cataract development and progression in diabetic rats through Nrf2/HO 1 signaling.Mol. Med. Rep.20192021017102410.3892/mmr.2019.10320 31173182
     [Google Scholar]
  68. CaiY. ZhangX. XuX. YuY. Effects of puerarin on the retina and STAT3 expression in diabetic rats.Exp. Ther. Med.20171465480548410.3892/etm.2017.5203 29285079
     [Google Scholar]
  69. ZhangH.W. ZhangH. GrantS.J. WanX. LiG. Single herbal medicine for diabetic retinopathy.Cochrane Database Syst. Rev.20181212CD007939 30566763
     [Google Scholar]
  70. MaR. ZhuR. WangL. GuoY. LiuC. LiuH. LiuF. LiH. LiY. FuM. ZhangD. Diabetic osteoporosis: A review of its traditional chinese medicinal use and clinical and preclinical research. Evidence-based Comple.Altern. Med.201620163218313
     [Google Scholar]
  71. WangX. ShiX. LuoX. ZhangD. Effect of Puerarin on the proliferation and differentiation of osteoblasts and the expression of type i collagen mrna in a high-glucose environment.Acta Endocrinol.2020163288294
     [Google Scholar]
  72. GuoC. XieJ. HongR. PanH. ZhangF. LiangY. Puerarin alleviates streptozotocin (STZ)-induced osteoporosis in rats through suppressing inflammation and apoptosis via HDAC1/] HDAC3 signaling.Biomed. & Pharma.2019115108570
     [Google Scholar]
  73. YinL. ChenX. LiN. JiaW. WangN. HouB. YangH. ZhangL. QiangG. YangX. DuG. Puerarin ameliorates skeletal muscle wasting and fiber type transformation in STZ-induced type 1 diabetic rats.Biomed. & Pharma.2021133110977
     [Google Scholar]
  74. HouB. ZhaoY. QiangG. YangX. XuC. ChenX. LiuC. WangX. ZhangL. DuG. Puerarin mitigates diabetic hepatic steatosis and fibrosis by inhibiting TGF- β signaling pathway activation in type 2 diabetic rats.Oxid. Med. Cell. Longev.2018201811310.1155/2018/4545321 30057680
     [Google Scholar]
  75. ZengX. ChenB. WangL. SunY. JinZ. LiuX. OuyangL. LiaoY. Chitosan@Puerarin hydrogel for accelerated wound healing in diabetic subjects by miR-29ab1 mediated inflammatory axis suppression.Bioact. Mater.20231965366510.1016/j.bioactmat.2022.04.032 35600974
     [Google Scholar]
  76. LiuW. LuH. RaoX. LiX. LuH. LiF. HeY. YuR. ZhongR. ZhangY. Enhanced treatment for cerebral ischemia-reperfusion injury of puerarin loading liposomes through neutrophils-mediated targeted delivery.Nano Res: Eng. Edi.20211446344643
     [Google Scholar]
/content/journals/emiddt/10.2174/0118715303287050240223073217
Loading
PUERARIN: A Potential Supplement for Diabetes and its Complications
Endocr Metab Immune Disord Drug Targets 25, 189 (2025); https://doi.org/10.2174/0118715303287050240223073217
/content/journals/emiddt/10.2174/0118715303287050240223073217
/content/journals/emiddt/10.2174/0118715303287050240223073217
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): Diabetes; diabetes mellitus; diabetic complications; drugs; insulin resistance; puerarin

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test